Status:
COMPLETED
Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Panic Disorder
Eligibility:
All Genders
20-60 years
Phase:
PHASE4
Brief Summary
Panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. The fear network involves many ...
Eligibility Criteria
Inclusion
- panic disorder
- 20-60 years
Exclusion
- history of major psychosis (schizophrenia or bipolar disorder), social phobia, obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic stress disorder. The acceptable score on the 17-item Hamilton Depression Rating Scale at entry into the study will be less than 17.
- patients and volunteers with alcohol dependence and current regular use of benzodiazepines will be excluded. Subjects with current or previous regular use of benzodiazepines will be excluded.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00767871
Start Date
March 1 2007
End Date
December 1 2008
Last Update
July 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710